Alnylam Pharmaceuticals Inc., of Cambridge Mass., and Sanofi Genzyme, a unit of Paris-based Sanofi SA, reported data from an ongoing phase II open-label extension study testing fitusiran in 33 patients with hemophilia A and B, with or without inhibitors.